Organigram Global Inc. (OGI) stock

OGINasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 16, 2025Score 4/30

$0.83−0.01 (-0.65%)

Close on Nov 13, 2026Market cap $111.41MP/E –Yield –

Organigram Global EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Organigram Global's EV/EBITDA was 29.3× on Nov 11, 2026, against 29.6× a year earlier. Over the last 3 years it ranged from 14.4× to 84.6×, with a median of 30.8×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	29.3×	−55.3
2025	Dec 31, 2025	84.6×	+54.9
2020	Oct 30, 2020	29.6×	−8.3
2019	Dec 31, 2019	37.9×	+22.6
2018	Dec 31, 2018	15.3×	–

Where these numbers come from

Parsed from the XBRL in Organigram Global's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Dec 19, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OGI.

Compare: OGI vs INCR · OGI vs CGC · OGI vs ACB · OGI vs VREOF · OGI vs LGND

Revenue growth77.8% · median 10.7%

Gross margin34.8% · median 35.9%

Operating margin-5.9% · median 1.3%

Company	Revenue	Growth
VREOF	$673.67M	+255.8%
CGC	C$308.32M	+10.7%
OGI	C$259.18M	+77.8%
LGND	$253.83M	+1.0%
INCR	–	–
ACB	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: September 30
Held by institutions: 5.7%
Auditor: PKF OConnor Davies, LLP
SEC CIK: 1620737

Advertisement
300 × 250

See a number that looks wrong?

Organigram Global EV/EBITDA

EV/EBITDA at the end of each year

More Organigram Global figures